Kathleen J May, F.N.P. Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 201 Tahoma Blvd, Suite 102, Yelm, WA 98597 Phone: 360-458-7761 |
Sharon J Olson, ARNP Nurse Practitioner - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 222 E Yelm Ave, Yelm, WA 98597 Phone: 360-458-0905 Fax: 360-458-0910 |
Fil Beth Gatmaitan Davis, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 202 Cullens St Nw, Yelm, WA 98597 Phone: 360-400-4800 Fax: 360-400-4821 |
Ms. Jalane Caroland, PMHNP-BC Nurse Practitioner - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 14958 91st Ave Se, Yelm, WA 98597 Phone: 360-955-1714 |
Brian Harvey, DNP, ARNP, FNP-BC Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 202 Cullens St Nw, Yelm, WA 98597 Phone: 360-400-4800 |
Emily Noel Auker, ARNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 17633 154th Ave Se, Yelm, WA 98597 Phone: 614-256-6511 |
Tynece L Buggs, FNP-C Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 202 Cullens St Nw, Yelm, WA 98597 Phone: 360-400-4800 |
Ms. Teresa Irene Garrison, ARNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 202 Cullens St Nw, Yelm, WA 98597 Phone: 360-400-4800 Fax: 360-400-4821 |
News Archive
TSO3 Inc., an innovator in low temperature sterilization technology for medical devices in healthcare settings, through the use of ozone (a cost effective, safe and eco-friendly method) today announced that it has filed a patent application in the United States seeking protection in that market as well as preserving rights in many other countries of recent innovations made to its sterilization systems, which enable both significantly faster and gentler cycles.
Fear memory encoding, the process responsible for persistent reactions to trauma-associated cues, is influenced by a sparse but potent population of inhibitory cells called parvalbumin-interneurons (PV-INs) in the amygdala, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online July 14 in the journal Neuron.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Montmorency tart cherry juice has gained a reputation as a recovery drink among elite and recreational exercisers, with research suggesting benefits for reducing strength loss and improving muscle recovery after intensive exercise.
An international research team headed by the University of Bern and the Netherlands Cancer Institute has developed 3D cell cultures in which genes can be specifically modified. They allow the study of genes that may cause therapy resistance in breast cancer.
› Verified 3 days ago